Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 14/20 | 0.57 |
| ▸ | EGFR | P00533 | 8/20 | 0.57 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | FECH | P22830 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.41 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6961006 | 0.84 | ERBB2 (0.54) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL11961092 | 0.81 | ERBB2 (0.49) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL13814713 | 0.79 | HTR2A (0.42) | KCNH2SCN5ASCN9ASLC6A4 | |
| SCHEMBL26172994 | 0.79 | ERBB2 (0.49) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL4798131 | 0.78 | ERBB2 (0.47) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL215985 | 0.78 | ERBB2 (0.50) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL1096558 | 0.78 | ERBB2 (0.59) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL12851559 | 0.77 | ERBB2 (0.46) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL9975265 | 0.77 | CSF1R (0.41) | ERBB2EGFRERBB3ERBB4 | |
| SCHEMBL13950791 | 0.76 | ERBB2 (0.46) | ERBB2EGFRERBB3ERBB4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021030711-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | ERBB2 1/4885EGFR 2/4885ERBB3 4/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | ERBB2 1/4885EGFR 2/4885ERBB3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.